Literature DB >> 10474275

Establishment of reference values for endocrine tests. II: Hyperprolactinemia.

R Le Moli1, E Endert, E Fliers, T Mulder, M F Prummel, J A Romijn, W M Wiersinga.   

Abstract

BACKGROUND: In patients with hyperprolactinemia, the thyrotropin-releasing hormone (TRH) stimulation test is widely applied to distinguish prolactinoma from other causes of hyperprolactinemia. In the present study, we established reference values for the plasma concentration of prolactin (PRL) and its response to TRH.
METHODS: Basal PRL and the PRL response to 400 micrograms TRH i.v. was determined in 50 subjects recruited from the general population, equally distributed according to sex and age between 20 and 69 years. PRL was determined by a fluoroimmunometric assay. Reference values are given as the observed range.
RESULTS: Plasma concentrations of PRL were 4.0-25 micrograms/l (median: 10.0 micrograms/l) in women and 0.5-19.0 micrograms/l (median: 8.5 micrograms/l) in men (p = 0.11). The peak PRL concentration after stimulation with TRH was slightly higher in women (median: 51 micrograms/l) than in men (median: 41 micrograms/l; p = 0.04) and was reached at t = 20 min in all subjects. The relative increase in plasma PRL (median: 440%) did not show a statistically significant effect of age or sex. In 12 subjects (24%), the relative increase in plasma PRL was lower than 250%, which has traditionally been considered the minimum cutoff for a normal response. There were no effects of smoking and alcohol, but regular ingestion of liquorice was associated with lower basal (p = 0.03) and lower stimulated (p = 0.05) plasma concentrations of PRL.
CONCLUSIONS: The present study provides reference values for basal and TRH-stimulated plasma concentrations of PRL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10474275     DOI: 10.1016/s0300-2977(99)00040-6

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  4 in total

1.  Prolactin as a predictor of endothelial dysfunction and arterial stiffness progression in menopause.

Authors:  G Georgiopoulos; I Lambrinoudaki; F Athanasouli; E Armeni; A Koliviras; A Augoulea; D Rizos; C Papamichael; A Protogerou; K Stellos; K Stamatelopoulos
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

2.  Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells.

Authors:  Fransiscus E Utama; Thai H Tran; Amy Ryder; Matthew J LeBaron; Albert F Parlow; Hallgeir Rui
Journal:  Endocrinology       Date:  2008-11-20       Impact factor: 4.736

3.  Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.

Authors:  Anne Q Reuwer; Brigitte M Sondermeijer; Suzanne Battjes; Rogier van Zijderveld; Danka J F Stuijver; Peter H Bisschop; Marcel Th B Twickler; Joost C M Meijers; Reinier O Schlingemann; Erik S Stroes
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

4.  The prolactin receptor is expressed in rheumatoid arthritis and psoriatic arthritis synovial tissue and contributes to macrophage activation.

Authors:  Man Wai Tang; Kris A Reedquist; Samuel Garcia; Bea Malvar Fernandez; Veronica Codullo; Elsa Vieira-Sousa; Vincent Goffin; Anne Q Reuwer; Marcel T Twickler; Daniëlle M Gerlag; Paul-Peter Tak
Journal:  Rheumatology (Oxford)       Date:  2016-09-10       Impact factor: 7.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.